Source comparison
PT-141 Onset Comparison — Routes and Formulations
Subcutaneous Injection 30–90 minutes 90–120 minutes 4–6 hours Systemic absorption → CNS receptor activation FDA-approved route; consistent pharmacokinetics Intranasal (discontinued) 20–60 minutes 60–90 minutes 3–5 hours Nasal mucosa absorption → faster CNS acc
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- 30–90 minutes
- 90–120 minutes
- 4–6 hours
- Systemic absorption → CNS receptor activation
- FDA-approved route; consistent pharmacokinetics
- Intranasal (discontinued)
- 20–60 minutes
- 60–90 minutes
- 3–5 hours
- Nasal mucosa absorption → faster CNS access
- Abandoned due to hypertensive adverse events
- Oral (not viable)
- N/A. Degraded before absorption
- N/A
- Peptide bond cleavage by gastric enzymes
- Not pharmacologically active via oral route
- Intramuscular (off-label)
- 25–70 minutes
- 75–110 minutes
- Faster depot release than subcutaneous fat
- Not studied in clinical trials; anecdotal only